Cymbalta gains indication for chronic musculoskeletal pain

Lilly announced that Cymbalta (duloxetine HCl) has gained an indication for the management of chronic musculoskeletal pain, including chronic osteoarthritis pain and chronic low back pain. Although the exact mechanism by which Cymbalta works to reduce chronic musculoskeletal pain is unknown, it is believed that Cymbalta helps lessen pain by enhancing the body’s natural pain suppressing system by increasing the activity of serotonin and norepinephrine in the brain and spinal cord.

Cymbalta is already approved for the treatment of major depressive disorder and generalized anxiety disorder, and to manage diabetic peripheral neuropathic pain and fibromyalgia.

For more information call (800) LILLY-RX or visit www.cymbalta.com.